Cited by 333Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and ManagementCancer Genomics and Diagnostics

The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index.

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Open access

Lee, J.H., Long, G.V., Boyd, S., Lo, S., Menzies, A.M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R.A., Mann, G.J., Kefford, R.F., Carlino, M.S., Rizos, H.·2017·Annals of Oncology

DOI 10.1093/annonc/mdx026

Open this paper in CoChat — free account Open PDF

Abstract

Background Programmed death 1 (PD1) inhibitors are now a foundation of medical management of metastatic melanoma. This study sought to determine whether circulating tumour DNA (ctDNA) provides useful early response and prognostic information.Patients and methods We evaluated the relationship between pre-treatment and early on treatment ctDNA and outcome in melanoma patients treated with PD1 inhibitors alone or in combination with ipilimumab.Results ctDNA was detected in 40/76 patients (53%) at baseline, and correlated with stage, LDH levels, disease volume and ECOG performance. RECIST response was 72% (26/36) in group A (undetectable ctDNA at baseline), 77% (17/22) in group B (elevated ctDNA at baseline but undetectable within 12 weeks of therapy) and 6% (1/18) in group C (elevated ctDNA at baseline and remained elevated during treatment). The median PFS was not reached in groups A and B and was 2.7 months for group C [hazard ratio (HR) 0.09; P < 0.001 for group A versus C, and 0.16; P < 0.001 for group B versus C]. The median OS was not reached for groups A and B and was 9.2 months for group C (HR 0.02; P < 0.001 for group A versus C and 0.14; P < 0.001 for group B versus C). The poor outcome measures associated with group C remained significant in multivariate analysis adjusted for LDH, performance status, tumour stage and disease volume. The predictive value for ctDNA for response was confirmed in a separate validation cohort (n = 29, P < 0.01).Conclusion Longitudinal assessment of ctDNA in metastatic melanoma patients receiving treatment with PD1 inhibitors is an accurate predictor of tumour response, PFS and OS. Patients who had a persistently elevated ctDNA on therapy had a poor prognosis, and this may guide combination and sequencing of subsequent therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdx026

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citation
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citation
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citation
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,725
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Ribas, A., Puzanov, I. J., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,590
Absolute quantification by droplet digital PCR versus analog real-time PCR
Hindson, C. M., Chevillet, J. R., Briggs, H. A., Gallichotte, E. N., Ruf, I. K., Hindson, B. J., Vessella, R. L., & Tewari, M. (2013) · Nature Methods · doi:10.1038/nmeth.2633 · Cited by 1,488

Flagged first, then by citations

Show all 25 references

2 of the 25 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 333

Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review
Ouwerkerk, W., van den Berg, M., van der Niet, S., Limpens, J., & Luiten, R. M. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000589 · Cited by 38
Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
Diefenbach, R. J., Lee, J., Menzies, A. M., Carlino, M. S., Long, G. V., Saw, R. P. M., Howle, J. R., Spillane, A. J., Scolyer, R. A., Kefford, R. F., et al. (2020) · Cancers · doi:10.3390/cancers12082228 · Cited by 39
Circulating tumour DNA and melanoma survival: A systematic literature review and meta-analysis
Gandini, S., Zanna, I., Angelis, S. P. D., Cocorocchio, E., Queirolo, P., Lee, J., Carlino, M. S., Mazzarella, L., Duso, B. A., Palli, D., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103187 · Cited by 40
Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition
Park, J., Diefenbach, R. J., Byrne, N., Long, G. V., Scolyer, R. A., Gray, E. S., Carlino, M. S., & Rizos, H. (2021) · Cancers · doi:10.3390/cancers13071740 · Cited by 37
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab
Awada, G., Jansen, Y. J. L., Schwarze, J. K., Tijtgat, J., Hellinckx, L., Gondry, O., Vermeulen, S., Warren, S. E., Schats, K., van Dam, P., et al. (2021) · Cancers · doi:10.3390/cancers13020168 · Cited by 36
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Remón, J., García‐Campelo, R., de Álava, E., Vera, R., Rodríguez‐Peralto, J. L., Rodríguez-Lescure, Á., Bellosillo, B., Garrido, P., Rojo, F., & Álvarez-Alegret, R. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02211-x · Cited by 37
ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab
Forthun, R. B., Hovland, R., Schuster, C., Puntervoll, H. E., Brodal, H. P., Namløs, H. M., Aasheim, L. B., Meza‐Zepeda, L. A., Gjertsen, B. T., Knappskog, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53917-5 · Cited by 34
Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
Garutti, M., Bonin, S., Buriolla, S., Bertoli, E., Pizzichetta, M. A., Zalaudek, I., & Puglisi, F. (2021) · Cancers · doi:10.3390/cancers13081819 · Cited by 38
Monitoring Melanoma Using Circulating Free DNA
Diefenbach, R. J., Lee, J., & Rizos, H. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0398-x · Cited by 36
Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors
Pedersen, J. G., Madsen, A. T., Gammelgaard, K. R., Pedersen, N. A., Sørensen, B. S., Øllegaard, T. H., & Jakobsen, M. R. (2020) · Cancers · doi:10.3390/cancers12061414 · Cited by 34
Circulating Tumour DNA in Melanoma—Clinic Ready?
Tivey, A., Britton, F., Scott, J.-A., Rothwell, D. G., Lorigan, P. C., & Lee, R. J. (2022) · Current Oncology Reports · doi:10.1007/s11912-021-01151-6 · Cited by 33
Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy
Chan, W. Y., Lee, J., Stewart, A., Diefenbach, R. J., Gonzalez, M., Menzies, A. M., Blank, C. U., Scolyer, R. A., Long, G. V., & Rizos, H. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03153-1 · Cited by 35
Circulating biomarkers predictive of tumor response to cancer immunotherapy
Lee, E. Y., & Kulkarni, R. P. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1659728 · Cited by 33
Cinnamaldehyde Enhances Antimelanoma Activity through Covalently Binding ENO1 and Exhibits a Promoting Effect with Dacarbazine
Zhang, W., Gao, J., Cheng, C., Zhang, M., Liu, W., Ma, X., Lei, W., Hao, E., Hou, X., Hou, Y., et al. (2020) · Cancers · doi:10.3390/cancers12020311 · Cited by 32
Current Trends in Circulating Biomarkers for Melanoma Detection
Huang, N. Ν., Lee, K., & Stark, M. S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.873728 · Cited by 32
Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotype
Albrecht, L. J., Hoewner, A., Griewank, K., Lueong, S., Neuhoff, N. V., Horn, P., Sucker, A., Paschen, A., Livingstone, E., Ugurel, S., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1090 · Cited by 31
Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise
Bird, B., Nally, K., Ronan, K. E., Clarke, G. A., Amu, S., Almeida, A. S., Flavin, R., & Finn, S. P. (2022) · Diagnostics · doi:10.3390/diagnostics12010124 · Cited by 29
The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma
Fattore, L., Ruggiero, C. F., Liguoro, D., Castaldo, V., Catizone, A., Ciliberto, G., & Mancini, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.645069 · Cited by 31
SLAMF8 expression predicts the efficacy of anti‐PD1 immunotherapy in gastrointestinal cancers
Zhang, Q., Cheng, L., Qin, Y., Kong, L., Shi, X., Hu, J. Y., Li, L., Ding, Z., Wang, T., Shen, J., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1347 · Cited by 30
A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma
Jackett, L. A., & Scolyer, R. A. (2019) · Cancers · doi:10.3390/cancers11122041 · Cited by 30
Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma
Warburton, L., Meniawy, T. M., Calapre, L., Pereira, M. R., McEvoy, A. C., Ziman, M. R., Gray, E. S., & Millward, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-75837-5 · Cited by 29
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
Tawbi, H. A., Robert, C., Brase, J. C., Gusenleitner, D., Gasal, E., Garrett, J., Savchenko, A., Görgün, G., Flaherty, K. T., Ribas, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004226 · Cited by 30
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)
Ascierto, P. A., Bifulco, C. B., Buonaguro, L., Emens, L. A., Ferris, R. L., Fox, B. A., Delgoffe, G. M., Galon, J., Gridelli, C., Merlano, M. C., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0798-3 · Cited by 28
Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy
Keller, L., Guibert, N. M., Casanova, A., Brayer, S., Farella, M., Delaunay, M., Gilhodes, J., Martin, E., Balagué, G., Favre, G., et al. (2018) · Acta Dermato Venereologica · doi:10.2340/00015555-3080 · Cited by 29
Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel
Gray, E. S., Witkowski, T., Pereira, M. R., Calapre, L., Herron, K., Irwin, D. L., Chapman, B. M., Khattak, M. A., Raleigh, J., Hatzimihalis, A., et al. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.12.001 · Cited by 27
Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review
Baltussen, J. C., Welters, M. J. P., Verdegaal, E. M. E., Kapiteijn, E., Schrader, A. M. R., Slingerland, M., Liefers, G., van der Burg, S. H., Portielje, J. E. A., & de Glas, N. A. (2021) · Cancers · doi:10.3390/cancers13246366 · Cited by 28
Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy: A review
Zdrenka, M., Kowalewski, A., Ahmadi, N., Sadiqi, R. U., Chmura, Ł., Borowczak, J., Maniewski, M., & Szylberg, Ł. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9265 · Cited by 30
Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study
Herbreteau, G., Vallée, A., Knol, A., Théoleyre, S., Quereux, G., Varey, É., Khammari, A., Dréno, B., & Denis, M. G. (2021) · Cancers · doi:10.3390/cancers13081826 · Cited by 26
PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma
Gibney, G. T., Zaemes, J. P., Shand, S., Shah, N. J., Swoboda, D. M., Gardner, K., Radfar, A., Petronic-Rosic, V. M., Reilly, M. J., Al‐Refaie, W. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002955 · Cited by 26
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
Hamid, O., Robert, C., DAUD, A. I., Carlino, M. S., Mitchell, T. C., Hersey, P., Schachter, J., Long, G. V., Hodi, F. S., Wolchok, J. D., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.013 · Cited by 25
Liquid biopsy for diagnostic and prognostic evaluation of melanoma
Slusher, N. J., Jones, N., & NONAKA, T. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1420360 · Cited by 29
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board
Dorman, K., Zhang, D., Heinrich, K., Reeh, L., Weiss, L., Haas, M., Beyer, G., Rössler, D. C., Goni, E., Renz, B. W., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00950-0 · Cited by 25
Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
Liang, H., Xu, Y., Chen, M., Zhong, W., Wang, M., & Zhao, J. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13367 · Cited by 25
The Multiple Potential Biomarkers for Predicting Immunotherapy Response—Finding the Needle in the Haystack
Adam, T., Becker, T. M., Chua, W. M., Bray, V., & Roberts, T. L. (2021) · Cancers · doi:10.3390/cancers13020277 · Cited by 25
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non‐small cell lung cancer patients
Zheng, Q., Hong, S., Huang, Y., Zhao, H., Yang, Y., Hou, X., Zhao, Y., Ma, Y., Zhou, T., Zhang, Y., et al. (2020) · Clinical and Translational Medicine · doi:10.1186/s40169-020-0269-y · Cited by 23
Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma
Gouda, M. A., Polívka, J., Huang, H. J., Treskova, I., Pivovarčíková, K., Fikrle, T., Woznica, V., Dustin, D. J., Call, S. G., Meric‐Bernstam, F., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100357 · Cited by 24
Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS ‐03 trial
Zang, J., Zhang, R., Jin, D., Xie, F., Shahatiaili, A., Wu, G., Zhang, Y., Zhao, Z., Du, P., Jia, S., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6166 · Cited by 23
Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma
Hoeijmakers, L. L., Reijers, I. L. M., & Blank, C. U. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0352 · Cited by 24
Multiplex Gene Profiling of Cell-Free DNA in Patients With Metastatic Melanoma for Monitoring Disease
Lin, S. Y., Huang, S. K., Huynh, K. T., Salomon, M. P., Chang, S., Marzese, D. M., Lanman, R. B., Talasaz, A. H., & Hoon, D. S. �. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00225 · Cited by 23
Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma
Brunsgaard, E. K., Bowles, T. L., Asare, E. A., Grossmann, K. F., Boucher, K. M., Grossmann, A. H., Jackson, J. A., Wada, D. A., Rathore, R., Budde, G. L., et al. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000892 · Cited by 22
Remodeling the tumor dormancy ecosystem to prevent recurrence and metastasis
Liang, Y., Chen, W., Zhang, Y., & Li, L. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02328-2 · Cited by 29
Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status
Po, J. W., Ma, Y., Balakrishna, B., Brungs, D., Azimi, F., SOUZA, P. D., & Becker, T. M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211866 · Cited by 22
Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects
Pilla, L., Alberti, A., di Mauro, P., Gemelli, M. T., Cogliati, V., Cazzaniga, M. E., Bidoli, P., & Maccalli, C. (2020) · Cancers · doi:10.3390/cancers12113456 · Cited by 24
Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
Huang, A., Zhang, X., & Zhou, J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00348-y · Cited by 23
Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients
Lin, S. Y., Orozco, J. I. J., & Hoon, D. S. �. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-97746-1_5 · Cited by 23
Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies
Jang, A., Lanka, S. M., Jaeger, E., Lieberman, A., Huang, M., Sartor, O. A., Mendiratta, P., Brown, J. R., Garcia, J. A., Farmer, T. E., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00131 · Cited by 21
Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
Aris, M., Mordoh, J., & Barrio, M. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01024 · Cited by 21
Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy
Seremet, T., Planken, S., Schreuer, M. S., Jansen, Y. J. L., Delaunoy, M., Housni, H. E., Líénard, D., del Mármol, V., Heimann, P., & Neyns, B. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000415 · Cited by 21
Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma
Martínez-Vila, C., Teixidó, C., Aya, F., Martín, R., González‐Navarro, E. A., Alós, L., de Anta, N. C., & Arance, A. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020861 · Cited by 22
Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay
Hsiehchen, D., Espinoza, M., Gerber, D. E., & Beg, M. S. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1963166 · Cited by 19
Anti-PD-1: When to Stop Treatment
Jansen, Y. J. L., van der Veldt, A. A. M., Awada, G., & Neyns, B. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01264-6 · Cited by 19
Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets
Dobre, E.-G., Constantin, C., & Neagu, M. T. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071136 · Cited by 19
An update on methods for detection of prognostic and predictive biomarkers in melanoma
Adeuyan, O. O., Gordon, E. R., Kenchappa, D., Bracero, Y., Singh, A. P., Espinoza, G., Geskin, L. J., & Saenger, Y. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1290696 · Cited by 21
Acquired Resistance to Immune Checkpoint Blockade Therapies
Zhao, X., Wangmo, D., Robertson, M. J., & Subramanian, S. (2020) · Cancers · doi:10.3390/cancers12051161 · Cited by 19
The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond BRAF Mutant Detection
Marsavela, G., Johansson, P. A., Pereira, M. R., McEvoy, A. C., Reid, A. L., Robinson, C., Warburton, L., Khattak, M. A., Meniawy, T. M., Amanuel, B., et al. (2020) · Cancers · doi:10.3390/cancers12123793 · Cited by 19
Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy
Strudel, M., Festino, L., Vanella, V., Beretta, M., Marincola, F. M., & Ascierto, P. A. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191205160007 · Cited by 18
The prognostic value of circulating tumor DNA in patients with melanoma: A systematic review and meta-analysis
Feng, S., Cen, X., Tan, R., Wei, S., & Sun, L. D. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101072 · Cited by 18
Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma
Takai, E., Omata, W., Totoki, Y., Nakamura, H. K., Shiba, S., Takahashi, A., Namikawa, K., Mori, T., Yamazaki, N., Shibata, T., et al. (2021) · Cancer Science · doi:10.1111/cas.15088 · Cited by 18
Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma
García‐Sancha, N., Corchado‐Cobos, R., Bellido-Hernández, L., Román‐Curto, C., Álvarez, E. C., Pérez‐Losada, J., Órfão, A., & Cañueto, J. (2021) · Cancers · doi:10.3390/cancers13205134 · Cited by 21
Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis
Zhao, Z., Bian, J., Zhang, J., Zhang, T., & Lu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.843707 · Cited by 18
Detection of metastases using circulating tumour DNA in uveal melanoma
Beasley, A. B., de Bruyn, D. P., Calapre, L., Al‐Ogaili, Z., Isaacs, T., Bentel, J. M., Reid, A. L., Dwarkasing, R. S., Pereira, M. R., Khattak, M. A., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05271-3 · Cited by 18
Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment
Yao, S., Han, Y., Yang, M., Jin, K., & Lan, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292861 · Cited by 19
Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma
Menzies, A. M., Lo, S., Saw, R. P. M., Gonzalez, M., Ch’ng, S., Nieweg, O., Shannon, K. F., Ferguson, P. M., Lee, J., Emmett, L., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.05.002 · Cited by 18
Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma
Diefenbach, R. J., Lee, J., Strbenac, D., Yang, J. Y. H., Menzies, A. M., Carlino, M. S., Long, G. V., Spillane, A. J., Stretch, J. R., Saw, R. P. M., et al. (2019) · Cancers · doi:10.3390/cancers11121905 · Cited by 19
Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?
Watson, G. A., Doi, J., Hansen, A. R., & Spreafico, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14355 · Cited by 17
Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
Herbreteau, G., Vallée, A., Knol, A., Théoleyre, S., Quereux, G., Frénard, C., Varey, É., Hofman, P. M., Khammari, A., Dréno, B., et al. (2020) · Cancers · doi:10.3390/cancers12071871 · Cited by 18
Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy
Fatima, S., Ma, Y., Safrachi, A., Haider, S., Spring, K. J., Vafaee, F., Scott, K. F., Roberts, T. L., Becker, T. M., & SOUZA, P. D. (2022) · Cancers · doi:10.3390/cancers14071669 · Cited by 18
Tailoring immunotherapy with liquid biopsy
Tie, J. (2020) · Nature Cancer · doi:10.1038/s43018-020-00113-4 · Cited by 17
Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers
Spiliopoulou, P., Vornicova, O., Genta, S., & Spreafico, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021294 · Cited by 19
Potential biomarkers for immunotherapy in non-small-cell lung cancer
Wang, X., Qiao, Z.-Y., Aramini, B., Lin, D. X., Li, X., & Fan, J. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10074-y · Cited by 18
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
Rozeman, E. A., Versluis, J. M., Sikorska, K., Hoefsmit, E. P., Dimitriadis, P., Rao, D., Lacroix, R., Grijpink-Ongering, L. G., López‐Yurda, M., Heeres, B. C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006821 · Cited by 18
Corresponding ctDNA and tumor burden dynamics in metastatic melanoma patients on systemic treatment
Egger, M. E., Alexander, E. M., Meter, T. L. V., Kong, M., Maung, A. A., Valdes, R., Hall, M. B., & Linder, M. W. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101883 · Cited by 17
Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: A pilot study
Alves, M. C., Fonseca, F. L. A., Yamada, A. M. T. D., Barros, L. A. D. R., Lopes, A., Silva, L. C. F. F., Luz, A. S., Cruz, F. J. S. M., & del Giglio, A. (2020) · Tumor Biology · doi:10.1177/1010428320919198 · Cited by 17
Promising clinical application of ctDNA in evaluating immunotherapy efficacy.
Li, L., Zhang, J., Jiang, X., & Li, Q. (2018) · Europe PMC (PubMed Central) · Cited by 16
Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma
Tachiki, L. M. L., Hippe, D. S., Silva, K. W., Hall, E. T., McCamy, W., Fritzsche, D., Perdue, A. M., Majovski, J., Pulliam, T. H., Goldstein, D. A., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03539-8 · Cited by 17
Biomarkers of immunotherapy response in breast cancer beyond PD-L1
Chic, N., Brasó‐Maristany, F., & Prat, A. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06421-2 · Cited by 17
Cell-Free DNA Diagnostics: Current and Emerging Applications in Oncology
Muluhngwi, P., Valdes, R., Fernandez-Botrán, R., Burton, E., Williams, B. J., & Linder, M. W. (2019) · Pharmacogenomics · doi:10.2217/pgs-2018-0174 · Cited by 16
Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis
Zheng, Y., Sun, H., Cong, L., Liu, C., Sun, Q., Wu, N., & Cong, X. (2021) · Journal of Oncology · doi:10.1155/2021/6660571 · Cited by 16
Promising and Minimally Invasive Biomarkers: Targeting Melanoma
Spiliopoulou, P., Lopes, C. D. H., & Spreafico, A. (2023) · Cells · doi:10.3390/cells13010019 · Cited by 16
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)
Ascierto, P. A., Agarwala, S. S., Botti, G., Budillon, A., Davies, M. A., Dummer, R., Ernstoff, M. S., Ferrone, S., Formenti, S. C., Gajewski, T. F., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1979-z · Cited by 15
Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression
Warburton, L., Calapre, L., Pereira, M. R., Reid, A. L., Robinson, C., Amanuel, B., Ziman, M. R., Millward, M., & Gray, E. S. (2020) · Cancers · doi:10.3390/cancers12113486 · Cited by 15
Update on Liquid Biopsy
Mayerhoefer, M. E., Kienzle, A., Woo, S., & Vargas, H. A. (2025) · Radiology · doi:10.1148/radiol.241030 · Cited by 18
Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial
Hsiehchen, D., Kainthla, R., Kline, H., Siglinsky, E., Ahn, C. W., & Zhu, H. (2025) · Nature Communications · doi:10.1038/s41467-025-60757-7 · Cited by 15
Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915
Long, G. V., Tang, H. T., Desai, K., Wang, S., Vecchio, M. D., Larkin, J., Ritchings, C., Huang, S., Baden, J. F., Balli, D., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012034 · Cited by 14
Comprehensive analysis of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs): A SEER database analysis of 767 cases
Song, H., Yang, S., Zhang, Y., Hua, Y., Kleeff, J. H., Liu, Q., & Liao, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1007317 · Cited by 14
Dynamic Treatment Stratification Using ctDNA
Vidal, J., Taus, Á., & Montagut, C. O. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-26439-0_14 · Cited by 14
Monitoring early dynamic changes of plasma cell-free DNA and pretreatment pre-albumin to predict chemotherapy effectiveness and survival outcomes in advanced non-small cell lung cancer
Chen, J., Shao, J., Zhang, X., Wei, S., Cai, H., & Gaoren, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-12 · Cited by 13
BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours
Kasi, P. M., Chakrabarti, S., Sawyer, S. D., Krainock, M. R., Poklepovic, A. S., Ansstas, G., Maninder, M., Malhotra, M., Ensor, J., Gao, L., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060342 · Cited by 13
Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation
Udagawa, S., Ooki, A., Shinozaki, E., Fukuda, K., Yamaguchi, K., & Osumi, H. (2023) · Cancers · doi:10.3390/cancers15051473 · Cited by 14
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)
Dayimu, A., Gupta, A., Matin, R., Nobes, J. P., Ruth Board, Payne, M., Rao, A. R., Fusi, A., Danson, S. J., Eccles, B., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113455 · Cited by 13
Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)
Ascierto, P. A., Brugarolas, J., Buonaguro, L., Butterfield, L. H., Carbone, D. P., Daniele, B., Ferris, R. L., Fox, B. A., Galon, J., Gridelli, C., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0377-z · Cited by 13
Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective
Poletto, S., Paruzzo, L., Nepote, A., Caravelli, D., Sangiolo, D., & Carnevale‐Schianca, F. (2023) · Cancers · doi:10.3390/cancers16010101 · Cited by 13
Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: a phase 2 clinical trial
Zhang, M., Zhang, G., Niu, Y., Zhang, G., Ji, Y., Yan, X., Zhang, X., Wang, Q., Jing, X., Wang, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45769-z · Cited by 12
Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer
Kwon, M. J. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01402-5 · Cited by 12
Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer
Peng, W.-W., Liu, Y., Sha, H., Wen, S., Fang, Y., & Zhou, G. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02586-2 · Cited by 12
Validation of Circulating Tumor DNA Assays for Detection of Metastatic Melanoma
Syeda, M. M., Wiggins, J. M., Corless, B. C., Spittle, C., Karlin-Neumann, G. A., & Polsky, D. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_7 · Cited by 12
Monitoring Immunotherapy Outcomes with Circulating Tumor Dna
Goldberg, S. B., & Patel, A. A. (2018) · Immunotherapy · doi:10.2217/imt-2018-0084 · Cited by 12
Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non‐small cell lung cancer
Cheng, L., Gao, G., Zhao, C., Wang, H., Yao, C. L., Yu, H., Yao, J., Li, F., Guo, L., Jian, Q., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6108 · Cited by 11
Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers
Li, M., Kaili, D., & Shi, L. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i1.19 · Cited by 12
Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report
Calapre, L., Warburton, L., Millward, M., & Gray, E. S. (2019) · BMC Cancer · doi:10.1186/s12885-019-6336-3 · Cited by 11

Authors: Lee, J. H., Long, G. V., Boyd, S., Lo, S., Menzies, A. M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R. A., Mann, G. J., Kefford, R. F., Carlino, M. S., & Rizos, H.
Affiliations: The University of Sydney (AU)
Macquarie University (AU)
Melanoma Institute Australia (AU)
Royal Prince Alfred Hospital (AU)
Corresponding author: Rizos, H.
ORCID: Lee, J.H.
Long, G.V.
Lo, S.
Menzies, A.M.
Guminski, A.
Jakrot, V.
Scolyer, R.A.
Mann, G.J.
Kefford, R.F.
Carlino, M.S.
Rizos, H.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2017-05
Volume: 28
Issue: 5
Pages: 1130-1136
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdx026
OpenAlex: W2588078993
Cited by: 333
References: 25
Citations by year: 2026: 22 · 2025: 21 · 2024: 16 · 2023: 52 · 2022: 28 · 2021: 51 · 2020: 48 · 2019: 43 · 2018: 39 · 2017: 12
FWCI: 17.23
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 917 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: National Health and Medical Research Council (1093017 and 1130423)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: circulating tumor DNA, metastatic melanoma, PD-1 inhibitors, ipilimumab, treatment response prediction, prognostic factors, progression-free survival, overall survival, longitudinal ctDNA monitoring, immune checkpoint inhibitors
MeSH terms: Circulating Tumor DNA, Ipilimumab, Aged, Antibodies, Anti-Idiotypic, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Biomarkers, Tumor, Neoplasms, Second Primary, Disease-Free Survival, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks